Stimulant Addiction Treatment: What Actually Works Without MAT

Stimulant use disorder — cocaine, methamphetamine, prescription amphetamines used problematically — has a specific problem that shapes treatment: there is no FDA-approved medication for stimulant use disorder. The pharmacological tools that anchor treatment for opioid, alcohol, and nicotine addiction don't exist here. This makes stimulant treatment behavioral-therapy-anchored in ways other substance categories aren't, and it makes the choice of program more important, not less.

This is a working guide to what evidence-based stimulant treatment looks like, why residential treatment can be clinically appropriate even without physiological withdrawal, and what questions to ask a program about their stimulant-specific expertise.

Why stimulant treatment is clinically different

Several features distinguish stimulant use disorder from other substance use disorders in ways that affect treatment design:

• No approved MAT. Multiple pharmacological candidates have been studied — bupropion, modafinil, topiramate, contingency management combined with medications — with modest and inconsistent results. As of 2026, no medication is FDA-approved for stimulant use disorder as MAT is for opioid or alcohol use disorder.
• Distinct withdrawal profile. Stimulant cessation doesn't produce the medically dangerous withdrawal syndrome of alcohol or benzodiazepines. What it does produce is severe fatigue, depression, sleep dysregulation, hyperphagia, and profound anhedonia — the "crash" — followed by weeks to months of gradually improving mood, sleep, and reward function.
• Powerful cue-reactivity. Environmental cues associated with use produce strong physiological and psychological cravings that can persist for years. This makes environmental disruption — one of residential treatment's main mechanisms — particularly relevant.
• High relapse rates in the first months. Stimulant use disorder has one of the higher early-relapse rates across substance categories, particularly in patients with high pre-treatment use and strong cue-linked triggers.
• Prominent co-occurring conditions. Depression, anxiety, and ADHD are highly prevalent in stimulant use disorder populations. Integrated treatment of co-occurring conditions is often the key intervention.

What actually works: the evidence base

Contingency management

Contingency management (CM) has the strongest evidence base of any behavioral intervention for stimulant use disorder. It's a structured incentive program: patients receive tangible rewards (vouchers, prizes, escalating value) for verified negative drug tests. The mechanism is straightforward — CM directly addresses the deficient reward-response in chronic stimulant use by providing external, immediate, tangible reinforcement for abstinence.

Multiple systematic reviews have documented CM's effectiveness for cocaine and methamphetamine use disorders, with effect sizes larger than most other behavioral interventions and improved treatment retention. Adoption in US treatment programs remains uneven due to funding structure and philosophical resistance. Ask specifically whether a program uses contingency management as part of stimulant treatment.

Cognitive Behavioral Therapy (CBT)

CBT for stimulant use disorder focuses on identifying use patterns, high-risk situations, coping skills for cravings, and relapse prevention. Solid evidence base, particularly when combined with contingency management. The Matrix Model — a structured, manualized CBT-based program originally developed for stimulant users — is widely used and has strong evidence support.

Community Reinforcement Approach (CRA)

CRA restructures the patient's environment to make non-drug reinforcers more available and accessible. Focused on employment, relationships, and prosocial activities. Evidence-supported particularly for cocaine and methamphetamine use disorders.

Motivational Interviewing (MI)

Effective for treatment engagement and enhancing motivation, particularly in early-stage patients or those with ambivalence. Usually incorporated into other treatment approaches rather than used alone.

Why residential is often the right container

Because stimulant withdrawal isn't physiologically dangerous, patients sometimes assume they don't need residential treatment. That misses several features that make residential clinically appropriate:

• Environmental separation. Cue-reactivity is one of the primary drivers of relapse. Physical removal from the environments, people, and stimuli associated with use is one of residential's main mechanisms.
• Sleep and mood stabilization. The post-acute stimulant withdrawal period (weeks to months of anhedonia, fatigue, sleep disruption, depression) is a high-risk window for relapse. Residential provides the structure that supports recovery of these functions.
• Depression and comorbidity management. Post-stimulant depression can be severe and can require pharmacological management. Residential settings provide the medication management and monitoring that supports this.
• Behavioral therapy dosing. Intensive daily behavioral therapy, including contingency management with more frequent testing, is easier to deliver in residential.
• Peer group building. The stimulant-specific peer group in residential treatment can be a substantial post-discharge support resource.

The anhedonia problem

One specific feature deserves emphasis: chronic stimulant use produces changes in the brain's reward system that make normal rewarding activities feel emotionally flat or unrewarding for weeks to months after cessation. Patients often experience this as depression, boredom, or "life has no color." It's a real neurochemical phenomenon (reduced dopamine transporter density, D2 receptor changes), and it's a primary driver of early relapse. Understanding it exists, that it improves gradually with sustained abstinence, and that the improvement is often nonlinear (with better and worse periods rather than steady progress) is important for patient endurance during this window.

Co-occurring conditions in stimulant use disorder

Rates of co-occurring conditions in stimulant use disorder are high. Common patterns:

• Depression — either pre-existing depression that stimulant use partially self-medicated, or depression triggered/exacerbated by chronic use.
• Anxiety disorders — including panic, generalized anxiety, and social anxiety. Stimulant use often exacerbates anxiety in the long term even when it produces short-term relief.
• ADHD — some patients with unrecognized ADHD self-medicate with stimulants. Diagnosis and appropriate treatment (which may include prescription stimulants under careful management) is a specialized clinical decision.
• Trauma-related disorders — PTSD and complex trauma frequently co-occur.
• Bipolar disorder — stimulant use disorder can mimic, mask, or interact with bipolar disorder in complex ways.

Integrated psychiatric care during residential treatment for stimulant use disorder is often the key clinical intervention — treating the substance use disorder without addressing the co-occurring condition is a common failure pattern.

Questions to ask a program

1. Do you use contingency management as part of stimulant treatment?
2. What CBT-based programming do you provide (Matrix Model, other structured programs)?
3. Who manages psychiatric care for patients with co-occurring depression, anxiety, or ADHD?
4. How do you address the post-acute anhedonia period during treatment?
5. What is your typical length of stay for stimulant use disorder patients?
6. What does aftercare look like for stimulant use disorder specifically?

Colombia specifics

Reputable Colombian residential programs targeting international patients staff psychiatrists and addiction medicine physicians (verifiable through ReTHUS at rethus.gov.co) capable of managing co-occurring psychiatric conditions during stimulant treatment. Behavioral therapy programming quality varies by program, and specific implementation of contingency management is less common in Colombia than in some US academic-affiliated programs — worth verifying directly at any facility you consider.

Realistic expectations

Stimulant use disorder is treatable, but the trajectory is often longer and more relapse-punctuated than the trajectory of alcohol or opioid use disorder patients on maintenance medication. The chronic-condition framework fits particularly well here: initial residential treatment plus intensive continuing care plus ongoing management of co-occurring conditions, with return-to-use treated as clinical information rather than treatment failure. Programs and patients that hold this framework tend to produce better long-term outcomes than programs and patients that expect linear improvement.